Since the addition of macrophage activators anti- CD40 and CpG improved the antitumor efficacy of RT and 14.18-IL2 immunocytokine in this “cold” tumor model (15, 23, 24) and in the B78 tumor model (33), it is possible that this CRI regimen may be improved for the 9464D-GD2 model by the addition of these or similar activators of innate immunity. This evidence concerns the gene IL2 and neoplasm.